Hang Su

Hang Su

Auto-generated profile, based on publicly available information

Hang Su

Department of Lymphoma, The Fifth Medical Center of the People's Liberation Army General Hospital, Beijing, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
TWTingyu Wang
Tingyu Wang
XSXiuhua Sun
Xiuhua Sun
LQLihua Qiu
Lihua Qiu
HSHang Su
Hang Su
JCJunning Cao
Junning Cao
LQLugui Qiu
Lugui Qiu
Purpose: To investigate the efficacy and safety of the novel orally active PI3Kδ inhibitor in relapsed and/or refractory patients with follicular lymphoma (FL) who had received at least two prior systemic treatments. Patients and Methods: Histologically confirmed relapsed and/or refractory patients with FL with disease progression after receiving second-line or greater systemic therapy were enrolled. Linperlisib was administered at 80 mg every day, orally in a 28-day cycle until disease progression or intolerable toxicity occurred. The primary outcome for the study was the objective response rate (ORR), with secondary outcomes including the duration of response (DOR), progression-free survival (PFS), overall survival (OS), disease control rate, and drug safety profile. Results: Of 114 screened relapsed and/or refractory patients with FL, 84 were enrolled in the full analysis set (FAS). The ORR of the 84 FAS patients was 79.8% [95% confidence interval (CI), 69.6–87.8, 67 patients], with 13 patients (15.5%) achieving a complete response and 54 patients (64.3%) with a partial response. The median DOR was 12.3 months (95% CI, 9.3–15.9). The median PFS was 13.4 months (95% CI, 11.1–16.7). The 12-month OS rate was 91.4% (95% CI, 82.7–95.8) and a median OS not reached by 42 months. The most frequent (>3%) treatment-related adverse events Grade ≥3 were infectious pneumonia (19.0%), neutropenia (15.5%), decreased lymphocyte count (4.8%), decreased leukocyte count (4.8%), increased lipase (3.6%), decreased platelet count (3.6%), hypertriglyceridemia (3.6%), and interstitial lung disease (3.6%). Conclusions: Linperlisib demonstrated compelling clinical activity and manageable tolerability for relapsed and/or refractory patients with FL who had received at least two prior systemic therapies.

8 January 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
YSYuqin Song
Yuqin Song
ZJZhengming Jin
Zhengming Jin
ZLZhi-Ming Li
Zhi-Ming Li
YLYanyan Liu
Yanyan Liu
LLLanfang Li
Lanfang Li
JZJun Zhu
Jun Zhu
Purpose: Patients with peripheral T-cell lymphomas (PTCL) in the relapsed or refractory (r/r) setting have only a limited number of therapies available, and the prognosis is extremely poor. SHR2554 is an oral inhibitor against EZH2, a rational therapeutic target for lymphomas. Patients and Methods: This was a multicenter, two-part, phase I study of SHR2554 in r/r mature lymphoid neoplasms. In part I, 350 mg twice daily was established as the recommended phase II dose (RP2D) based on the findings during dose escalation and expansion; subsequently, selected lymphoma subtypes were recruited in clinical expansion cohorts to receive SHR2554 at RP2D. Here, we provide an in-depth assessment of SHR2554 at RP2D in subpopulation with r/r PTCL. Results: Twenty-eight patients were included for analysis (17 angioimmunoblastic T-cell lymphoma and 11 not otherwise specified). Eighteen (64%) patients had received ≥2 lines of previous anticancer therapies. The objective response rate was 61% [95% confidence interval (CI), 41–78]. Responses were still ongoing in 59% (10/17) of the responders; estimated median duration of response was 12.3 months (95% CI, 7.4–not reached). Median progression-free survival was 11.1 months (95% CI, 5.3–22.0), and 12-month overall survival rate was 92% (95% CI, 72–98). The most common grade 3 or 4 treatment-related adverse events were decreased platelet count [nine (32%)] as well as decreased white blood cell count, decreased neutrophil count, and anemia [four (14%) for each]. No treatment-related deaths were reported. Conclusions: This extended follow-up analysis further supports SHR2554 as a therapeutic opportunity for patients with r/r PTCL.

25 November 2025
Verified
Other
Open access
TWTingyu Wang
Tingyu Wang
XSXiuhua Sun
Xiuhua Sun
LQLihua Qiu
Lihua Qiu
HSHang Su
Hang Su
JCJunning Cao
Junning Cao
LQLugui Qiu
Lugui Qiu
Number and frequency of TRAE that led to discontinuation from the trial


25 November 2025
Verified
Other
Open access
TWTingyu Wang
Tingyu Wang
XSXiuhua Sun
Xiuhua Sun
LQLihua Qiu
Lihua Qiu
HSHang Su
Hang Su
JCJunning Cao
Junning Cao
LQLugui Qiu
Lugui Qiu
Comparison of PI3K inhibitor toxicities and their efficacies for relapsed and/or refractory indolent lymphoma treatments